Research
Hormonal
GLP-1 analogues (liraglutide and semaglutide) enable significant weight loss (approx. 14%) in obese patients with end-stage lung disease, thereby bridging the gap to lung transplantation eligibility when dietary and exercise interventions fail.
If you have severe lung disease and a BMI that bars you from transplant, ask your care team about GLP-1 medications (like semaglutide or liraglutide). This case shows they can help you lose enough weight to qualify for surgery when diet and exercise aren't enough, even while taking steroids.
LimitedSupportsLOW confidence
She had a rapid response to GLP- 1 therapy with over 14 kg of weight loss (14% of original body weight) over 6 months... She was listed for lung transplantation once sufficient weight loss was achieved.
Why this rating
Single case report; lacks control group and generalizability.
Source
Weight loss with GLP-1 analogues in preparation for transplantation
Marissa O’Callaghan et al. · BMJ Case Reports · 2024
DOI 10.1136/bcr-2023-256099
case_report · n=1Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →